ReviewFrontiers in cell and developmental biology2026
OverlappING and DivergING roles of ING4 and ING5 in cancer, differentiation and development.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The INhibitor of Growth (ING) proteins are plant homeodomain (PHD) zinc-finger epigenetic readers that recognize trimethylated lysine 4 of histone H3 (H3K4me3) and couple it to lysine-acetyltransferase (KAT) or -deacetylase (KDAC) activity on chromatin. ING4 and ING5 are among the family's closest paralogs, which share a four-domain architecture and high sequence identity, with divergence concentrated outside the PHD finger. Earlier reviews focused either on the family as a whole or on the individual INGs. This paper is the first to directly compare ING4 and ING5, including their structures, functions within KAT complexes, and roles in cancer and development, noting where they overlap and diverge. Either paralog can occupy the ING position in HBO1 (KAT7) complexes, whereas only ING5 is found in MOZ and MORF (KAT6A/B) complexes. In cancers, ING4 and ING5 generally act as tumor suppressors but can also promote malignancy and stemness. The bulk of evidence for mechanistically explaining the effects of ING4/5 in cancers comes from ectopic overexpression studies. In differentiation, ING5 has been investigated far more than ING4, and the roles of the two mostly diverge: ING5 participates in maintaining stemness in neural, epidermal, and brain tumor initiating cell lines, as well as proliferation of mesenchymal stem cells, whereas ING4 was found to restrain hematopoietic stem cell self-renewal, promote prostate epithelial differentiation, but promote stemness of renal cell carcinoma cells. They nonetheless compensate for one another in embryonic survival, since either paralog alone prevents the arrest seen in double knockouts. The key remaining questions include what determines the structural basis of ING5's MOZ/MORF selectivity, what the precise conditions are under which they substitute for one another, how exactly ING4 and ING5 can be targeted in cancer therapy, and whether the roles of the two paralogs are conserved across species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.